uniQure NV

Most Recent

  • uploads///mental health _
    Company & Industry Overviews

    Analysts Rate Voyager Therapeutics and Its Peers in April

    Voyager Therapeutics is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases.

    By Kenneth Smith
  • uploads///red blood cells _
    Company & Industry Overviews

    uniQure Stock Rose 35.7% Yesterday—Here’s Why

    On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.

    By Daniel Collins
  • uploads///QURE pipeline
    Company & Industry Overviews

    uniQure: Its Promising Research Pipeline

    uniQure (QURE) is advancing a pipeline of gene therapies that are developed internally and externally. It has a collaboration with Bristol-Myers Squibb (BMY).

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    BioMarin Pharmaceutical and Its Promising Research Pipeline

    Stocks focused on gene therapy have garnered strong investor interest in 2018. In this series, we’ll analyze four of those companies.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.